|Source||Humanized (from mouse)|
|(what is this?)|
Epratuzumab (planned trade name LymphoCide) is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as systemic lupus erythematosus (SLE).
A clinical trial for relapsed adult acute lymphoblastic leukemia (ALL) has reported initial results.
Results have been published for a phase II trial in untreated follicular lymphoma.
Early results from a phase II trial for Diffuse large B-cell lymphoma (DLBCL) were encouraging.
The manufacturers in August 2009 announced success in early trials against SLE, and started two Phase III clinical trials.
July 2015 : Both phase III trials (EMBODY1/2) for SLE failed to meet their primary endpoint.
Mechanism of action
Elevated CD22 and other B-cell receptor (BCR) proteins are associated with SLE. "Epratuzumab's mechanism of action transfers these BCR proteins to helper cells called effector cells which reduces B-cell destruction and epratuzumab's impact on the body's immune system" via a process called trogocytosis. (Other SLE therapies destroy B-cells which compromises the immune system.)
- Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties Clinical Cancer Research Vol. 9, September 1, 2003 free full text
- Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab Clinical Cancer Research Vol. 11, July 15, 2005 free full text
- Micallef et al. (2011). "Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma." (PDF). Blood. 118 (15): 4053–61. doi:10.1182/blood-2011-02-336990.
- Reuters: UCB and Immunomedics Announce Positive Results for Epratuzumab Phase IIb Study in Systemic Lupus Erythematosus (SLE)
- Epratuzumab flunks two Phase 3 studies; Immunomedics plummets 42% premarket. July 28 2015